Ursodeoxycholic Acid

[SDL] Ursodeoxycholic Acid Capsule 250 mg

[SDL] Ursodeoxycholic Acid Suspension 50 mg/mL

[SDL] Ursodeoxycholic Acid Tablet 500 mg

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

01/09/2020 Ursodeoxycholic acid for treating primary biliary cirrhosis

The Ministry of Health’s Drug Advisory Committee has recommended:

• Ursodeoxycholic acid 250 mg capsule, 500 mg tablet and 50 mg/ml suspension for treating primary biliary cirrhosis in patients without decompensated hepatic cirrhosis.

Subsidy status

[R] Ursodeoxycholic acid 250 mg capsule, 500 mg tablet and 50 mg/ml suspension are recommended for inclusion on the MOH Standard Drug List (SDL).

[R] Ursodeoxycholic acid 50 mg/ml suspension does not have regulatory approval with the Health Sciences Authority (HSA). The responsibility of prescribing an unregistered product to patients lies with the treating clinician. Before treatment is started, it is important to consider the availability of other suitable registered alternatives and inform the patient or their carer that the product is unregistered.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration